First line modified Folfirinox versus gemcitabine for advanced pancreatic cancer: A single institution retrospective experience
Background: Advanced pancreatic cancer (APC) is a highly lethal malignancy which has one of the worst treatment outcomes. Modified (m)FOLFIRINOX is an intense but a proven treatment approach with a survival benefit for APC. Although mFOLFIRINOX demonstrated survival benefit compared with gemcitabine...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Turkiye Klinikleri
2019-04-01
|
| Series: | Journal of Oncological Sciences |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336418300761 |